Stifel analyst James Condulis reiterated a Buy rating and $50.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE